Literature DB >> 15215186

Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior.

Ernest Y Tan1, Michelle Mujoomdar, Jonathan Blay.   

Abstract

Dipeptidyl peptidase IV (DPPIV) is a multifunctional cell-surface protein that, as well as having dipeptidase activity, is the major binding protein for adenosine deaminase (ADA) and also binds extracellular matrix proteins such as fibronectin and collagen. It typically reduces the activity of chemokines and other peptide mediators as a result of its enzymatic activity. DPPIV is aberrantly expressed in many cancers, and decreased expression has been linked to increases in invasion and metastasis. We asked whether adenosine, a purine nucleoside that is present at increased levels in the hypoxic tumor microenvironment, might affect the expression of DPPIV at the cell surface. Treatment with a single dose of adenosine produced an initial transient (1 to 4 hours) modest (approximately 10%) increase in DPPIV, followed by a more profound (approximately 40%) depression of DPPIV protein expression at the surface of HT-29 human colon carcinoma cells, with a maximal decline being reached after 48 hours, and persisting for at least a week with daily exposure to adenosine. This down-regulation ofDPPIV occurred at adenosine concentrations comparable to those present within the extracellular fluid of colorectal tumors growing in vivo, and was not elicited by inosine or guanosine. Neither cellular uptake of adenosine nor its phosphorylation was necessary for the down-regulation of DPPIV. The decrease in DPPIV protein at the cell surface was paralleled by decreases in DPPIV enzyme activity, binding of ADA, and the ability of the cells to bind to and migrate on cellular fibronectin. Adenosine, at concentrations that exist within solid tumors, therefore acts at the surface of colorectal carcinoma cells to decrease levels and activities of DPPIV. This down-regulation of DPPIV may increase the sensitivity of cancer cells to the tumor-promoting effects of adenosine and their response to chemokines and the extracellular matrix, facilitating their expansion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15215186      PMCID: PMC1618535          DOI: 10.1016/S0002-9440(10)63299-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  64 in total

1.  A collagen-binding glycoprotein on the surface of mouse fibroblasts is identified as dipeptidyl peptidase IV.

Authors:  B Bauvois
Journal:  Biochem J       Date:  1988-06-15       Impact factor: 3.857

2.  Direct evidence for the binding of rat liver DPP IV to collagen in vitro.

Authors:  C Hanski; T Huhle; R Gossrau; W Reutter
Journal:  Exp Cell Res       Date:  1988-09       Impact factor: 3.905

3.  Distribution of adenosine deaminase complexing protein (ADCP) in human tissues.

Authors:  W N Dinjens; J ten Kate; E P van der Linden; J T Wijnen; P M Khan; F T Bosman
Journal:  J Histochem Cytochem       Date:  1989-12       Impact factor: 2.479

4.  Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix.

Authors:  G A Piazza; H M Callanan; J Mowery; D C Hixson
Journal:  Biochem J       Date:  1989-08-15       Impact factor: 3.857

5.  Complete release of adenosine deaminase from mouse lymphocytes stabilized by low-pH acetate.

Authors:  S Senesi; G Freer; M Gasperini; G Batoni; M Campa
Journal:  Biochim Biophys Acta       Date:  1988-01-18

6.  Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells.

Authors:  C L Pethiyagoda; D R Welch; T P Fleming
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

7.  Adenosine deaminase complexing protein (ADCP) expression and metastatic potential in prostatic adenocarcinomas.

Authors:  W N Dinjens; J Ten Kate; J A Kirch; H J Tanke; E P Van der Linden; H F Van den Ingh; G J Van Steenbrugge; P Meera Khan; F T Bosman
Journal:  J Pathol       Date:  1990-03       Impact factor: 7.996

8.  Characterization of the adenosine deaminase-adenosine deaminase complexing protein binding reaction.

Authors:  W P Schrader; C A West; A D Miczek; E K Norton
Journal:  J Biol Chem       Date:  1990-11-05       Impact factor: 5.157

9.  5'-Nucleotidase activity and adenosine formation in stimulated, hypoxic and underperfused rat heart.

Authors:  J P Headrick; R J Willis
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

10.  Hypoxic fractions in xenografted human colon tumors.

Authors:  J T Leith; G Padfield; L Faulkner; S Michelson
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

View more
  14 in total

1.  Constitutive activation of BMP signalling abrogates experimental metastasis of OVCA429 cells via reduced cell adhesion.

Authors:  Trevor G Shepherd; Michelle L Mujoomdar; Mark W Nachtigal
Journal:  J Ovarian Res       Date:  2010-02-26       Impact factor: 4.234

Review 2.  Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?

Authors:  V Kumar
Journal:  Purinergic Signal       Date:  2012-12-28       Impact factor: 3.765

Review 3.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

4.  The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells.

Authors:  Emilie C Lefort; Jonathan Blay
Journal:  Clin Exp Metastasis       Date:  2011-02-05       Impact factor: 5.150

5.  Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.

Authors:  John Stagg; Upulie Divisekera; Nicole McLaughlin; Janelle Sharkey; Sandra Pommey; Delphine Denoyer; Karen M Dwyer; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

Review 6.  DPPIV/CD26: a tumor suppressor or a marker of malignancy?

Authors:  Aline Beckenkamp; Samuel Davies; Júlia Biz Willig; Andréia Buffon
Journal:  Tumour Biol       Date:  2016-03-04

Review 7.  Targeting immunosuppressive adenosine in cancer.

Authors:  Dipti Vijayan; Arabella Young; Michele W L Teng; Mark J Smyth
Journal:  Nat Rev Cancer       Date:  2017-10-23       Impact factor: 60.716

Review 8.  Immunity, inflammation and cancer: a leading role for adenosine.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Nat Rev Cancer       Date:  2013-11-14       Impact factor: 60.716

9.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

Review 10.  Does Oral Apigenin Have Real Potential for a Therapeutic Effect in the Context of Human Gastrointestinal and Other Cancers?

Authors:  Eva F DeRango-Adem; Jonathan Blay
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.